Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
Titel:
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
Auteur:
Bhalla, Sheena Fattah, Farjana J. Ahn, Chul Williams, Jessica Macchiaroli, Alyssa Padro, Jonathan Pogue, Meredith Dowell, Jonathan E. Putnam, William C. McCracken, Nigel Micklem, David Brekken, Rolf A. Gerber, David E.